Lisa Suennen is Managing Partner at Venture Valkyrie Consulting, LLC, a consulting firm providing advisory services to companies, organizations and private equity firms in the healthcare field.
Additionally, Lisa is a Senior Advisor to Psilos Group, a healthcare-focused venture capital and growth equity firm that focuses on the healthcare information technology, healthcare services and medical device sectors. Lisa was a co-founder of Psilos Group and a Partner at the firm from 1998-2014.
Prior to Psilos, Lisa was at Merit Behavioral Care (formerly American Biodyne, Inc), an $800mm behavioral healthcare company where she held various senior executive roles from its early start-up days through exit. Previously, Lisa held various positions in marketing and product management in companies in the high technology field
Lisa is currently a a Board Member of the Dignity Health Foundation, and Board Member of health IT company Beyond Lucid Technologies, a Board Member of medical device company AngioScore, a member of the Qualcomm Life Advisory Board, and an Advisor to the California Health Care Foundation Innovation Fund. Lisa also serves as an Advisor to innovation consulting firm Accelevate, Inc. She previously served as a member of the Advisory Board of the U.S. Health and Human Services Office of the National Coordinator Investing in Innovations program.
Lisa holds an M.A. in political science, a B.A. in political science and a B.A. in mass communications, all from the University of California, Berkeley, where she is now Vice Chair of the National Advisory Council of the Institute of Governmental Studies at the University. Lisa is also a visiting lecturer at the U.C. Berkeley Haas School of Business where she teaches the annual course on healthcare venture capital.
Lisa also writes a widely read blog on healthcare and healthcare investing at www.venturevalkyrie.com. She has recently published her first book, entitled: Tech Tonics, Can Passionate Entrepreneurs Heal Healthcare with Technology, coauthored with Dr. David Shaywitz.

Stacy Feld joined Physic Ventures in January 2009, where she leads the investment activities in personalized health. Her interests include science-based innovations that transform care for the health consumer and bring more precision to the prevention, diagnosis, and treatment of chronic diseases. Additionally, Stacy has been actively involved in the design and execution of business incubation and spin-off opportunities. Stacy is on the board of T2 Biosystems and an observer on the board of Own Products. Prior to joining Physic, Stacy was in business development positions at Genentech and Third Wave Technologies. Stacy currently serves as an advisor on the Springboard Enterprises Life Sciences Council and to the UCSF Clinical and Translational Research Institute T1 Catalyst Program.